Multiple sclerosis marker identified:
This article was originally published in Clinica
Executive Summary
A new marker for multiple sclerosis (MS) has been identified by an Italian-German research team. The protein marker, CD39, is thought to completely disappear in patients with the disease. CD39 is found on the surface of a subgroup of protective immune cells - suppressor cells - which are strikingly reduced in MS patients. In normal individuals, CD39 is thought to curb inflammation in the central nervous system during the course of the disease. The research team, based at the Fondazione Santa Lucia, in Rome, Italy, and the Max Delbruck Center for Molecular Medicine, in Berlin-Buch, Germany, hopes that the future will show whether the marker will become clinically useful. The findings appear in the August 15 issue of Blood.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.